Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ)
CNY 7.43
(-9.06%)
CNY 7.43
(-9.06%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -129.14 Million CNY | 27.48% |
| 2022 | -178.08 Million CNY | 14.5% |
| 2021 | -208.27 Million CNY | -70.62% |
| 2020 | -122.07 Million CNY | -378.19% |
| 2019 | -25.52 Million CNY | 73.39% |
| 2018 | -95.94 Million CNY | -128.63% |
| 2017 | -41.96 Million CNY | 21.46% |
| 2016 | -53.43 Million CNY | -231.55% |
| 2015 | -16.11 Million CNY | -2370.52% |
| 2014 | 709.81 Thousand CNY | 101.72% |
| 2013 | -41.33 Million CNY | -1257.59% |
| 2012 | -3.04 Million CNY | -125.44% |
| 2011 | 11.96 Million CNY | 252.86% |
| 2010 | -7.83 Million CNY | 76.2% |
| 2009 | -32.9 Million CNY | 59.81% |
| 2008 | -81.87 Million CNY | 37.77% |
| 2007 | -131.55 Million CNY | -747.92% |
| 2006 | -15.51 Million CNY | -10.65% |
| 2005 | -14.02 Million CNY | -484.68% |
| 2004 | -2.39 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -169.52 Million CNY | -43.05% |
| 2024 Q1 | -118.5 Million CNY | 8.24% |
| 2024 Q3 | -216.89 Million CNY | -27.94% |
| 2023 FY | -129.14 Million CNY | 27.48% |
| 2023 Q4 | -129.14 Million CNY | -22.24% |
| 2023 Q1 | -181.96 Million CNY | -2.18% |
| 2023 Q2 | -207.29 Million CNY | -13.92% |
| 2023 Q3 | -105.64 Million CNY | 49.03% |
| 2022 Q2 | -201.62 Million CNY | 3.22% |
| 2022 Q1 | -208.33 Million CNY | -0.02% |
| 2022 Q3 | -206.71 Million CNY | -2.53% |
| 2022 Q4 | -178.08 Million CNY | 13.85% |
| 2022 FY | -178.08 Million CNY | 14.5% |
| 2021 Q4 | -208.27 Million CNY | -14.78% |
| 2021 Q3 | -181.45 Million CNY | -10.69% |
| 2021 Q2 | -163.93 Million CNY | -8.31% |
| 2021 Q1 | -151.35 Million CNY | -23.99% |
| 2021 FY | -208.27 Million CNY | -70.62% |
| 2020 Q4 | -122.07 Million CNY | -80.82% |
| 2020 FY | -122.07 Million CNY | -378.19% |
| 2020 Q1 | -5.24 Million CNY | 79.47% |
| 2020 Q2 | -48.15 Million CNY | -818.84% |
| 2020 Q3 | -67.5 Million CNY | -40.2% |
| 2019 Q1 | -26.93 Million CNY | 71.93% |
| 2019 FY | -25.52 Million CNY | 73.39% |
| 2019 Q3 | 35.75 Million CNY | 27.66% |
| 2019 Q4 | -25.52 Million CNY | -171.41% |
| 2019 Q2 | 28 Million CNY | 203.97% |
| 2018 Q3 | -52.28 Million CNY | -36.25% |
| 2018 Q1 | -32.73 Million CNY | 21.99% |
| 2018 FY | -95.94 Million CNY | -128.63% |
| 2018 Q2 | -38.37 Million CNY | -17.22% |
| 2018 Q4 | -95.94 Million CNY | -83.52% |
| 2017 Q3 | -12.59 Million CNY | 67.26% |
| 2017 Q2 | -38.45 Million CNY | -9.32% |
| 2017 Q1 | -35.18 Million CNY | 34.16% |
| 2017 Q4 | -41.96 Million CNY | -233.26% |
| 2017 FY | -41.96 Million CNY | 21.46% |
| 2016 Q3 | -9.47 Million CNY | -184.02% |
| 2016 Q4 | -53.43 Million CNY | -464.0% |
| 2016 Q1 | -5.37 Million CNY | 66.65% |
| 2016 FY | -53.43 Million CNY | -231.55% |
| 2016 Q2 | -3.33 Million CNY | 37.94% |
| 2015 Q2 | 5.81 Million CNY | 41.65% |
| 2015 FY | -16.11 Million CNY | -2370.52% |
| 2015 Q4 | -16.11 Million CNY | -3885.4% |
| 2015 Q3 | -404.38 Thousand CNY | -106.95% |
| 2015 Q1 | 4.1 Million CNY | 478.5% |
| 2014 Q2 | -39.17 Million CNY | -139.56% |
| 2014 Q3 | -23.2 Million CNY | 40.77% |
| 2014 Q4 | 709.81 Thousand CNY | 103.06% |
| 2014 Q1 | -16.35 Million CNY | 60.44% |
| 2014 FY | 709.81 Thousand CNY | 101.72% |
| 2013 Q3 | 1.32 Million CNY | 131.41% |
| 2013 Q4 | -41.33 Million CNY | -3229.47% |
| 2013 Q1 | -8.86 Million CNY | -191.07% |
| 2013 FY | -41.33 Million CNY | -1257.59% |
| 2013 Q2 | -4.2 Million CNY | 52.55% |
| 2012 Q3 | 11.24 Million CNY | 23.31% |
| 2012 FY | -3.04 Million CNY | -125.44% |
| 2012 Q4 | -3.04 Million CNY | -127.08% |
| 2012 Q2 | 9.11 Million CNY | -47.86% |
| 2012 Q1 | 17.49 Million CNY | 46.13% |
| 2011 Q3 | 16 Million CNY | 149.2% |
| 2011 FY | 11.96 Million CNY | 252.86% |
| 2011 Q4 | 11.96 Million CNY | -25.2% |
| 2011 Q1 | -6.01 Million CNY | 23.18% |
| 2011 Q2 | 6.42 Million CNY | 206.75% |
| 2010 Q1 | -18.77 Million CNY | 42.94% |
| 2010 Q4 | -7.83 Million CNY | 4.76% |
| 2010 Q3 | -8.22 Million CNY | 70.45% |
| 2010 Q2 | -27.82 Million CNY | -48.19% |
| 2010 FY | -7.83 Million CNY | 76.2% |
| 2009 Q4 | -32.9 Million CNY | 31.83% |
| 2009 Q3 | -48.26 Million CNY | 21.24% |
| 2009 Q2 | -61.27 Million CNY | 2.85% |
| 2009 Q1 | -63.07 Million CNY | 22.96% |
| 2009 FY | -32.9 Million CNY | 59.81% |
| 2008 FY | -81.87 Million CNY | 37.77% |
| 2008 Q1 | -125.35 Million CNY | 4.72% |
| 2008 Q2 | -117.62 Million CNY | 6.17% |
| 2008 Q3 | -117.34 Million CNY | 0.24% |
| 2008 Q4 | -81.87 Million CNY | 30.23% |
| 2007 Q4 | -131.55 Million CNY | -615.47% |
| 2007 Q2 | -19.19 Million CNY | 0.0% |
| 2007 FY | -131.55 Million CNY | -747.92% |
| 2007 Q3 | -18.38 Million CNY | 4.18% |
| 2006 FY | -15.51 Million CNY | -10.65% |
| 2006 Q4 | -15.51 Million CNY | 0.0% |
| 2005 FY | -14.02 Million CNY | -484.68% |
| 2004 FY | -2.39 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 935.92 Million CNY | 113.798% |
| Zhejiang Zhenyuan Share Co., Ltd. | -320.75 Million CNY | 59.739% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 580.71 Million CNY | 122.238% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 520.61 Million CNY | 124.805% |
| Yifan Pharmaceutical Co., Ltd. | 1.29 Billion CNY | 109.958% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 2.88 Billion CNY | 104.483% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | -562.43 Million CNY | 77.039% |
| Boai NKY Medical Holdings Ltd. | -230.36 Million CNY | 43.941% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | -1.1 Billion CNY | 88.354% |